Evaxion Biotech AS (EVAX)

NASDAQ
Currency in USD
Disclaimer
0.869
+0.010(+1.16%)
Closed
After Hours
0.836-0.033(-3.844%)
Day's Range
0.8210.880
52 wk Range
0.4703.100
Prev. Close
0.859
Open
0.88
Day's Range
0.821-0.88
52 wk Range
0.47-3.1
Volume
33,464
Average Vol. (3m)
116,618
1-Year Change
-67.34%
Shares Outstanding
27,662,484
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
9.333
Upside +974.028%

People Also Watch

0.173
GRTX
-0.69%
0.128
EZGO
-4.12%
0.230
BCEL
-13.21%
6.400
MEDS
+1.27%
0.411
IMPL
+4.80%

Evaxion Biotech AS Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.

Income Statement